KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Shares Outstanding (Diluted Average): 2010-2025

Historic Shares Outstanding (Diluted Average) for Regeneron Pharmaceuticals (REGN) over the last 14 years, with Sep 2025 value amounting to $108.9 million.

  • Regeneron Pharmaceuticals' Shares Outstanding (Diluted Average) fell 6.28% to $108.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.9 million, marking a year-over-year decrease of 6.28%. This contributed to the annual value of $115.1 million for FY2024, which is 1.23% up from last year.
  • As of Q3 2025, Regeneron Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $108.9 million, which was down 0.91% from $109.9 million recorded in Q2 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $116.2 million during Q3 2024, and registered a low of $108.9 million during Q3 2025.
  • For the 3-year period, Regeneron Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $113.4 million, with its median value being $113.9 million (2023).
  • In the last 5 years, Regeneron Pharmaceuticals' Shares Outstanding (Diluted Average) increased by 2.89% in 2022 and then decreased by 6.28% in 2025.
  • Regeneron Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $112.2 million in 2021, then grew by 1.16% to $113.5 million in 2022, then increased by 0.18% to $113.7 million in 2023, then increased by 1.23% to $115.1 million in 2024, then dropped by 6.28% to $108.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $108.9 million in Q3 2025, compared to $109.9 million in Q2 2025 and $111.2 million in Q1 2025.